Echo gets European go-ahead for needle-free Symphony trial; Norwegian nano-needles could force cellular delivery;

> Echo Therapeutics' ($ECTE) Symphony CGM System, a needle-free delivery device the company is developing for use as a glucose monitoring system, garnered acceptance from its Notified Body in Europe for a clinical trial plan. Release

> Nano-needles developed by Norwegian researchers may be used to force drugs into cells by impaling them from a tiny field of spikes. Article

> Arrowhead Research ($ARWR) filed with the FDA to begin a Phase I trial of its RNAi-based candidate for the treatment of hepatitis B. Release

> Drug-delivery company Acrux filed a lawsuit over claims that Perrigo Israel Pharmaceuticals infringed a patent of its delivery platform, Axiron. Release

> Swedish pharmaceutical company Oasmia has developed a combination cancer therapy with a unique drug-delivery system that allows the products to effectively act in tandem. WSJ report

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.